Avir Green Hills Biotechnology AG
🇦🇹Austria
Clinical Trials
5
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza, Avian
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- AVIR Green Hills Biotechnology AG
- Target Recruit Count
- 36
- Registration Number
- NCT03745274
- Locations
- 🇷🇺
Research Institute of Influenza, Russian Academy of Medical Sciences, Saint Petersburg, Russian Federation
Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza, Human
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- AVIR Green Hills Biotechnology AG
- Target Recruit Count
- 80
- Registration Number
- NCT01369862
- Locations
- 🇦🇹
Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria
Dose Finding Study of Single Dose GHB11L1 in Healthy Adults
Phase 2
Completed
- Conditions
- Influenza, Human
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- AVIR Green Hills Biotechnology AG
- Target Recruit Count
- 49
- Registration Number
- NCT01078701
- Locations
- 🇦🇹
Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria
Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- AVIR Green Hills Biotechnology AG
- Target Recruit Count
- 32
- Registration Number
- NCT00741806
- Locations
- 🇦🇹
Dept of Clinical Pharmacology, Medical University Vienna, Vienna, Austria
Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Seasonal Human Influenza
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- AVIR Green Hills Biotechnology AG
- Target Recruit Count
- 48
- Registration Number
- NCT00724997
- Locations
- 🇦🇹
Medical University Vienna, Vienna General Hospital, Dpmt. of Clinical Pharmacology, Vienna, Austria
News
No news found